Dr. Dreicer discusses efficacy of androgen receptor pathway inhibitors in mCSPC


Robert Dreicer, MD, explains how intensifying treatment through the combination of androgen-deprivation therapy and androgen receptor pathway inhibitors (eg, abiraterone acetate [Zytiga], enzalutamide [Xtandi], and apalutamide [Erleada]) has improved outcomes in patients with metastatic castration-sensitive prostate cancer. Dreicer is deputy director, UVA Cancer Center, director, Solid Tumor Oncology in the Division of Hematology/Oncology, and a professor of medicine and urology, University of Virginia Health System.

Related Videos
Paul E. Dato, MD, an expert on prostate cancer
Charles Parker, MD, answers a question during a Zoom video interview
Dr Daniel Allen Hamstra
Dr Daniel Allen Hamstra
3D illustration of prostate cancer cells | Image Credit: © Dr_Microbe - stock.adobe.com
Dr Daniel Allen Hamstra
Dr Daniel Allen Hamstra
Related Content
© 2023 MJH Life Sciences

All rights reserved.